Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-01-31

Study Completion Date

2003-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy and safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Registry of IgA Nephropathy in Chinese Children

NCT03015974

IgA Nephropathy Proteinuria in Nephrotic Range Immunosuppressive Treatment

RECRUITING

Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy

NCT00301600

IGA Nephropathy

COMPLETED NA

The Clinical Efficacy of DFPP in Patients With AAGN

NCT02294344

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

TERMINATED NA

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

NCT01451710

IgA Nephropathy

COMPLETED NA

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

NCT07098897

IgA Nephropathy (IgAN)

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lipoprotein glomerulopathy is characterized by nephritic syndrome glomerular protein thrombi and lipid abnormalities, particularly with an elevated level of plasma apoprotein E (apoE).There are no efficiency way to treat lipoprotein glomerulopathy. We firstly successfully treat 2 patients by protein A immunoadsorption with remarkable decreased urine protein and reduction of lipoprotein thrombi on repeated renal biopsy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

immunoadsorption

Group Type PLACEBO_COMPARATOR

immunoadsorption

Intervention Type PROCEDURE

immunoadsorption

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

immunoadsorption

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. A new diagnosis of lipoprotein glomerulopathy proved by histology and serology
2. Age 15\~60 years, sex free

Exclusion Criteria

1. Serum creatinine \> 500 umol/l
2. Severe viral infection(HBV, HCV, CMV) within 3 months of first randomization or known HIV infection
3. Congenital or acquired immunodeficiency
4. Patients with severe infection or central nervous system symptoms
5. Immediately life-threatening organ manifestations (e.g. lung haemorrhage or massive gastro-intestinal bleeding, heart failure due to pericarditis or myocarditis, liver dysfunction measured on at least 2 separate occasion)

Minimum Eligible Age

15 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes